应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台» 学术交流区» 论文翻译 » 论文翻译求助完结子版 » 求助，谢谢
91/1返回列表
查看: 1394  |  回复: 8
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看

木子8210

银虫 (小有名气)

[求助] 求助，谢谢

Description:
This patent application claims the benefit of priority under 35 U.S.C. §119 of German Patent Application No. 199 55 190.1, filed Nov. 16, 1999. German Patent Application No. 199 55 190.1 is incorporated herein in its entirety by reference.
The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for manufacturing these and highly pure, stable, intermediate products.
From document PCT/EP99/03212 novel derivatives of 3,3-diphenylproprylamines are known.
These are valuable prodrugn for the treatment of urinary incontinence and other spasmodic complaints, which overcome the disadvantage of the active substances available to date, namely inadequate absorption of the active substance by biological membranes or the unfavourale metabolism of these.
Furthermore these novel prodrugs have improved pharmacokinetic characteristics compared with Oxybutynin and Tolterodin.
Preferred compounds from the group of these novel derivatives of 3,3-diphenylpropylarines are esters of aliphatic or aromatic carboxylic acids with the general formula A referred to below  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl or unsubstituted or substituted phenyl. These can occur in their optical isomers form as racemic mixtures and in the form of their individual enantiomers.
Compounds with the structure of formula A do, however, have low solubility in water. This restricts their oral bioavailability.
Finally, monoesters of the structure, as shown in formula A, have a tendency towards intermolecular transesterification. During long periods of storage, therefore, as the content of the compounds with the structure of general formula A drops an increase in diesters and free diol can be detected.
Basically salts of the compounds of general formula A can be obtained if solutions of the compounds of formula A (base component) are purified with solutions of acids in suitable solvents, but the salts obtained in the form of solid matter can prove to be altogether amorphous and/or hygroscopic and cannot be directly crystallized from the normal solvents either. Such salts have inadequate chemical stability to be galenically processed as valuable pharmaceutically active substances.
Surprisingly, it has now been found that the abovementioned disadvantages can be avoided if compounds with the structure of general formula A, once they have been prepared under a special reaction process, are converted with a physiologically compatible inorganic or organic acid with general formula H-X, in which − X represents the respective acid residue, into their respective salt with general formula I.  
The problem for the present invention is therefore to provide highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, that avoid the stated disadvantages and are well suited to use in pharmaceutical-technical formulations and can be processed into these.
A further problem for the present invention is to provide a method for manufacturing such highly pure, crystalline, stable compounds in the form of their salts, as well as highly pure, stable intermediate products.
The final problem for the invention is to provide a method for manufacturing the abovementioned compounds with which a high yield of the products of the process and the respective intermediate products can be obtained chemo- or regioselectively.
This problem is solved in that highly pure, crystalline, stable compounds of the 3,3-diphenylpropylamines in the form of their salts with general formula I are provided,  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid.
In accordance with a design of the invention the salts of general formula I can contain the respective acid residue X − of the acids mentioned below:
•       
o        hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(−-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.
In accordance with a further design form of the invention R-configured compounds with general formula 2 are provided  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid.
In accordance with an advantageous design form of the invention the compounds in the form of their salts of general formula 2 can contain the respective acid residue X − of the acids mentioned below:
•       
o        hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(−-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.
Preferred compounds of the present invention are the salts
•       
o        R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate ester hydrogen fumarate and
o        R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate ester hydrochloride hydrate.
Furthermore, compounds are preferred in which R stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-(1-cyclo-propyl-methanoyloxy)-phenyl, 4-(1-cyclobutyl-methanoyloxy)-phenyl, 4-(1-cyclohexyl-methanoyloxy)-phenyl or 4-(2,2-dimethyl-propanoyloxy)-phenyl and X denotes chloride.
Particular preference is for [(R)-3-(2-{1-[4-(1-cyclopropyl-methanoyloxy)-phenyl]-methano yloxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl- ammonium chloride, [(R)-3-(2-{1-[4-(1-cyclobutyl-methanoyloxy)-phenyl]-methanoy loxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium chloride, [(R)-3-(2-{1-[4-(1-cyclohexyl-methanoyloxy)-phenyl]-methanoy loxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium chloride, [(R)-3-(2-{1-[4-(2,2-dimethyl-propanoyloxy)-phenyl]-methanoy loxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium chloride, {(R)-3-[2-(1-cyclopropyl-methanoyloxy)-5-hydroxymethyl-pheny l]-3-phenyl-propyl}-diisopropyl-ammonium chloride, {(R)-3-[2-(1-cyclobutyl-methanoyloxy)-5-hydroxymethyl-phenyl ]-3-phenyl-propyl}-diisopropyl-ammonium chloride, {(R)-3-[2-(1-cyclopentyl-methanoyloxy)-5-hydroxymethyl-pheny l]-3-phenyl-propyl}-diisopropyl-ammonium chloride and {(R)-3-[2-(1-cyclohexyl-methanoyloxy)-5-hydroxymethyl-phenyl ]-3-phenyl-propyl}-diisopropyl-ammonium chloride.
In the compounds of the present invention the expression “alkyl” preferably stands for a straight-chain or branched-chain hydrogen group with between 1 and 6 C-atoms. Special preference is for methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl and hexyl. The expression “cycloalkyl” designates cyclical hydrogen groups, that have between 3 and 10 hydrogen atoms, that may also contain suitable substitutes in place of the hydrogen atoms.
The expression “phenyl” designates a —C 6 H 5 -group that may be substituted or unsubstituted. Suitable substitutes can be, for example, alkyl, alkoxy, halogen, nitro and amine. The expression “alkoxy” has, with respect to the alkyl component, the same meaning as already given above for “alkyl”. Suitable halogens are fluorine, chlorine, bromine and iodine atoms
The present invention also includes methods for manufacturing the compounds in accordance with the invention of general formula I as well as valuable intermediate products.
The method is characterised by chemo- and regioselectivity.
Compounds of General Formula I  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid, are that
•       
o        a) a compound of formula III  
is split with a hydrogenation agent to form a compound of formula V  
whereupon
o        b) the compound of formula V so obtained is converted with agent, in order to give a compound of formula VI  
which
o        c) is converted with an acylation agent, in order to obtain of formula A  
in which R has the significance stated above, which d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula I  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, unsubstituted or substituted phenyl and X− is the acid residue of a physiologically compatible inorganic or organic acid.
In accordance with the invention, for the manufacture of the compounds of general formula I hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(−-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.
In accordance with an advantageous further development of the invention a method for the manufacture of R-configured compounds of the general formula 2 is described,  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid, in that
•       
o        a) a compound of formula 3  
is split with a hydrogenation agent to form a compound of formula 5  
whereupon
o        b) the compound of formula 5 so obtained is converted with a reducing agent, in order to give a compound of formula 6  
which
o        c) is converted with an acylation agent, in order to obtain a compound of formula 1  
in which R has the significance stated above, which
o        d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula 2  
in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, unsubstituted or substituted phenyl and X− is the acid residue of a physiologically compatible inorganic or organic acid.
Advantageously in order to obtain compounds of general formula 2, in accordance with the method hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(−-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+) -glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.
Particular advantageously, on the basis of the crystalline R-(−-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)be nzoic acid methyl ester, the highly pure, crystalline intermediate product R-(−-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzo ic acid methyl ester is prepared, which is reduced to R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylp henol, is finally acylated in a suitable manner and is then converted with a physiologically compatible inorganic or organic acid under spontaneous crystallization to the respective highly pure, crystalline, stable salt.
Depending on the acid chloride used, compounds of general formula 1 are obtained,  
in which R denotes C 1 -C 6 -alkyl, in particular isopropyl, C 3 -C 10 -cycloalkyl or unsubstituted or substituted phenyl.
回复此楼

» 猜你喜欢
1楼 2010-04-23 22:24:45
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

meng851124

木虫 (正式写手)

【答案】应助回帖

楼主什么意思？是翻译中文么？不说清楚~~~
赞一下 回复此楼
2楼2010-04-23 22:55:14
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

very小强

新虫 (初入文坛)
翻译成中文 谢谢
回复此楼
3楼2010-04-24 15:31:48
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

FePt

木虫 (正式写手)
lz太彪悍了吧。。。

专利翻译要是在专门机构做，不少钱吧
赞一下 回复此楼
4楼2010-04-24 16:36:07
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

melody-yhl

木虫 (著名写手)

职业写手
1700多字，有点多哦，呵呵，要300块，至少
赞一下 回复此楼
专利代理人
5楼2010-04-24 17:44:57
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

melody-yhl

木虫 (著名写手)

职业写手
量比较多啊，家里硬件跟不上，回头上班若有时间，再试看看，呵呵
赞一下 回复此楼
专利代理人
6楼2010-04-24 17:49:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

木子8210

银虫 (小有名气)
引用回帖:
Originally posted by 木子8210 at 2010-04-23 22:24:45:
Description:
This patent application claims the benefit of priority under 35 U.S.C. §119 of German Patent Application No. 199 55 190.1, filed Nov. 16, 1999. German Patent Application No. 199 55 1 ...

是翻译成中文
回复此楼
7楼2010-04-24 22:54:20
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

davidyanli

铜虫 (初入文坛)

【答案】应助回帖

内容已删除
赞一下 回复此楼
8楼2010-05-19 00:16:48
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

davidyanli

铜虫 (初入文坛)

【答案】应助回帖

★ ★ ★
wypward(金币+3):这是谷歌翻译的吧！但还是谢谢参与 2010-05-24 09:22:36
　　描述:
　　该专利申请要求优先权的35岁以下的编119德国中华民国专利申请案号(55 190.1、归档。199年11月16日。德国的专利申请号190.1 199 55一同被整合,以供参考。
　　本发明关切的高纯度、水晶、稳定的混合物,3-diphenylpropylamines小说的衍生3的形式的一种方法,他们的盐、高纯度,生产这些、稳定、中间产品。
　　从文件EP99/03212 PCT / 3,3-diphenylproprylamines衍生物的小说是众所周知的。
　　这些都是珍贵的prodrugn治疗性尿失禁和其他船上投诉,克服不利的活性物质可到目前为止,即不足的活性物质的吸收由生物膜或unfavourale代谢。
　　而且这些小说已经改善代谢特点热点和Tolterodin Oxybutynin相比。
　　优先化合物的这些小说中有3个,3-diphenylpropylarines衍生的脂肪或芳香羧酸酯酸与一般公式是指以下
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl或unsubstituted或取代苯。这些可以发生在他们的光学异构体用表格的形式混合物和个人对映体。
　　化合物的结构,然而,一个做公式水溶性较低。这种限制他们的口腔生物利用度。
　　最后,使结构,如图配方,有一间以倾向。在长期贮存,因此,为内容的化合物的结构,增加的一般表达式,在其中一个滴醇能被探测到,免费。
　　基本上盐的通用公式的化合物是可以解决的公式的化合物(组件基)的纯化解酸在适当的溶剂,但是盐的形式获得固体物质不能证明是共晶和/或吸湿性,不能直接从正常的溶剂结晶。这样的盐不足的化学稳定性是galenically处理为价值”活性物质。
　　令人惊讶的是,它现在已经发现上述缺点可以避免的化合物的结构一般公式,一旦他们已经准备下一个特别的反应过程,为有生理兼容的无机或有机酸和一般公式,H-X−X代表各自的酸性渣,为各自的盐与一般的公式。
　　本发明的问题,因此提供的高纯度、水晶、稳定的混合物,3-diphenylpropylamines小说的衍生3的形式,避免了他们的盐陈述弊端,非常适合用于pharmaceutical-technical配方,可加工成这些。
　　进一步的问题,本发明提供一种高纯度为制造这样,水晶,稳定化合物的形式的盐,以及高纯度、稳定的中间体。
　　最后的问题是提供了一种方法发明制造上述化合物和高产的产品的工艺及各自的中间产品可以获得——或者可以化疗。
　　这个问题已经解决,高纯度、水晶、稳定化合物的三、3-diphenylpropylamines的盐的形式与一般公式我,
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的无机或有机酸。
　　按照设计的一般公式,发明了盐,我可以包含了各自的酸性渣X−以下的氨基酸。
　　•
　　啊,hydrobromic盐酸酸、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、马来酸、富马酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、柠檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、没食子酸、马尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、邻苯二甲酸、四种羧酸或orotic酸。
　　依照进一步设计的一般公式R-configured发明和2个被提供
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的无机或有机酸。
　　依照一个有利的设计形式的发明的形式的化合物的一般公式的盐可容纳2×−各自的酸性渣酸下面提到:
　　•
　　啊,hydrobromic盐酸酸、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、马来酸、富马酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、柠檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、没食子酸、马尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、邻苯二甲酸、四种羧酸或orotic酸。
　　本发明的优先化合物的盐
　　•
　　o R -(+)- 2 -(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate富氢酯和
　　o R -(+)- 2 -(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate酯盐酸盐保湿。
　　再者,化合物的首选,cyclobutyl R代表cyclopropyl,cyclopentyl,cyclohexyl、4 -(2)-phenyl 1-cyclo-propyl-methanoyloxy,4 -(2)-phenyl 1-cyclobutyl-methanoyloxy,4 -(2)-phenyl 1-cyclohexyl-methanoyloxy或4 -(2)-phenyl 2-dimethyl-propanoyloxy和X表示。
　　特别偏爱是[(R)- 3 -(2 - { 1 - 4 -(1-cyclopropyl-methanoyloxy)-phenyl]-methano yloxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl -氯化铵,[(R)- 3 -(2 - { 1 - 4 -(1-cyclobutyl-methanoyloxy)-phenyl]-methanoy loxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium氯、[(R)- 3 -(2 - { 1 - 4 -(1-cyclohexyl-methanoyloxy)-phenyl]-methanoy loxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium氯、[(R)- 3 -(2 - { 1 - 4 -(2)-phenyl]-methanoy 2-dimethyl-propanoyloxy loxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium氯、{(R)- 3 -(2 -(1-cyclopropyl-methanoyloxy)-5-hydroxymethyl-pheny]-3-phenyl-propyl } -diisopropyl-ammonium氯、{(R)- 3 -(2 -(1-cyclobutyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl } -diisopropyl-ammonium氯、{(R)- 3 -(2 -(1-cyclopentyl-methanoyloxy)-5-hydroxymethyl-pheny]-3-phenyl-propyl } -diisopropyl-ammonium氯和{(R)- 3 -(2 -(1-cyclohexyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl } -diisopropyl-ammonium氯。
　　在这个化合物的本发明表达"烷基“最好是代表了一种straight-chain或branched-chain氢集团在1到6 C-atoms。特殊偏好、乙酸乙酯、醋酸丙对甲基异丙酯、醋酸异丁,,,pentyl和hexyl。表达" cycloalkyl”指明周期性氢团体,有3 - 10个氢原子,也可能包含了合适的替代品代替氢原子。
　　表达"苯基”指明了-C 6小时5 -group可替代或unsubstituted。合适的替代品,例如、醇酸、氧、卤素,硝基和三聚氰胺。表达"中",就烷基的组成部分,已给以上含义相同的“烷基”。适合有氟、氯离子、卤素溴碘原子
　　本发明也包括方法生产化合物的发明,按照一般公式我以及宝贵的中间体。
　　这个方法的特点是化学-和区域选择性。
　　我的一般公式
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的无机或有机酸,是那样
　　•
　　一)的化合物啊。配方
　　用一个分裂形成一种化合物加氢剂的配方V吗
　　于是
　　o b)的转换公式,用了V的代理人,以给一组配方VI
　　,
　　o c)转换为原料,经酰化剂,以为了得到的公式
　　在上述的意义[j]. d),与生理兼容无机物转化为酸或有机化合物的形成
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl,unsubstituted或取代苯和X−是酸性渣的生理兼容的无机或有机酸。
　　依照这项发明,为制造的化合物的通用公式我盐酸、hydrobromic酸、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、马来酸、富马酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、柠檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、没食子酸、马尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、邻苯二甲酸、四种羧酸或orotic酸。
　　依照一个有利的进一步发展的发明了一种化合物,R-configured制造的一般公式,二是描述,
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的无机或有机酸,在那
　　•
　　一个复合的阿三级方程式
　　用一个分裂形成一种化合物加氢剂的配方
　　于是
　　o b)的转换公式5所以取得与还原剂,为了给一个公式
　　,
　　o c)转换为原料,经酰化剂,以为了获得了一级方程式
　　在上述的意义[j],它
　　阿d)转化为有生理兼容的无机或有机酸形成化合物的配方2
　　在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl,unsubstituted或取代苯和X−是酸性渣的生理兼容的无机或有机酸。
　　为了获得成分资料库的通用公式,依照《中华人民共和国hydrobromic盐酸、酸法、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、马来酸、富马酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、柠檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、没食子酸、马尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、邻苯二甲酸、四种羧酸或orotic酸。
　　特定资料库的基础上,-4-benzyloxy-3水晶R -(−是nzoic——(3-diisopropylamino-1-phenyl-propyl酸甲酯、高纯度、中间产品的R -(3 -(3-diisopropylamino-phenyl-propyl−-4-hydroxy-benzo ic酸甲酯制备,降至R -(+)- 2 -(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylp henol,终于在一个合适的方式、酰化和生理上然后转换兼容无机或有机酸下结晶的自发的高纯度、水晶、稳定的盐。
　　根据酸氯化合物的一般公式,1,
　　在R代表C 1 -C 6 -alkyl,尤其是异丙醇、丙三-C 10 -cycloalkyl或unsubstituted或取代苯。
赞一下(1人) 回复此楼
9楼2010-05-19 00:21:55
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 木子8210 的主题更新
91/1返回列表
普通表情 龙 兔 虎 猫
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[论文投稿] 售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急 +3 ASdOkHsho7FD 2026-08-28 4/200 2026-08-29 14:13 by jCd0dEvKHShX
[基金申请] 麻烦专家们看看评委们的意见（F口面上） +5 gdd2018 2026-08-28 10/500 2026-08-29 14:10 by Jacob678
[基金申请] 面上意见出来了 +4 黄鸟于飞Chao 2026-08-29 4/200 2026-08-29 14:06 by Jacob678
[找工作] 售SCI文章，我:8O5.5.1.O.54,科目齐全,可+急 +3 ASdOkHsho7FD 2026-08-28 6/300 2026-08-29 11:51 by jCd0dEvKHShX
[考研] 售一区SCI文章T0P，我:8O.551.O54,科目全,可十急 +4 ASdOkHsho7FD 2026-08-28 6/300 2026-08-29 11:40 by jCd0dEvKHShX
[找工作] 售SCI文章，我:8O5.5.1.O.54,科目齐全,可+急 +4 ASdOkHsho7FD 2026-08-28 6/300 2026-08-29 11:29 by jCd0dEvKHShX
[基金申请] 国自然面上复盘~欢迎讨论 (金币+15) +14 晴天加油 2026-08-26 15/750 2026-08-29 11:06 by biily
[基金申请] 2026年叶企孙基金 +4 bud_bud 2026-08-27 7/350 2026-08-29 07:23 by foolishmani
[基金申请] 系统查不到 +11 董八千 2026-08-26 11/550 2026-08-28 18:06 by Leogzhya
[基金申请] 基金系统什么内容也没有 30+4 winsaint 2026-08-27 9/450 2026-08-28 11:06 by maolC
[基金申请] 申请删除本帖 +6 lyz123lyz 2026-08-27 7/350 2026-08-27 17:31 by 宁静致远sy
[基金申请] 为什么 国际(地区)合作与交流项目 没有放榜？ 10+3 majunge000 2026-08-26 11/550 2026-08-27 08:42 by 北京莱茵编辑
[基金申请] 我不理解！ +15 Edward_pc 2026-08-26 23/1150 2026-08-26 20:34 by zzuzxg
[基金申请] 能否退出参与的面上项目解除限项 +23 koalala 2026-08-24 26/1300 2026-08-26 14:29 by 宝贝虫子
[基金申请] 国合里面能看到了 +7 一怀馨秋 2026-08-26 7/350 2026-08-26 11:23 by zhaosm1982
[职场人生] 学生撞见辅导员送外卖，第二天全班都沉默了 +3 鲸鱼融金_浙江_� 2026-08-22 3/150 2026-08-26 09:01 by zzuzxg
[基金申请] 国合现在查不到了吗？ +10 chengyan1220 2026-08-24 20/1000 2026-08-26 08:57 by peasantsprig
[基金申请] 某些机构，以效率低为荣，以效率低作为存在感 +9 yuleib84 2026-08-25 10/500 2026-08-25 17:14 by alexon
[基金申请] 如果此刻你正在为国基感到焦虑，不妨来听听这首《基金之外》 +8 scalable 2026-08-24 8/400 2026-08-25 12:52 by jnhyjjm
[基金申请] 没有任何消息-是不是就凉了 +9 图啦图啦 2026-08-24 10/500 2026-08-25 11:59 by 南海小哥
信息提示
关闭
请填处理意见
关闭